InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
October 3, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, is reporting to shareholders on plans for the 2024 year end. Highlights of the report include news about its two acquisition targets: Evofem Biosciences (OTCQB: EVFM) has reported $7.8 million in revenue for the first six months of 2024, while Appili Therapeutics Inc. (TSX: […]
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
September 24, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, has reported that its acquisition target, Evofem Biosciences (OTCQB: EVFM), a women’s health company, has filed a preliminary proxy. The proxy is seeking stockholder approval of transactions outlined under the Amended and Restated Merger Agreement with Aditxt and Adifem Inc., a wholly owned subsidiary of […]
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test
September 20, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration agreement with Evofem Biosciences (OTCQB: EVFM), a women’s health company. According to the announcement, the agreement involves Pearsanta’s blood-based diagnostic test for endometriosis, which affects an estimated 190 million women globally. The […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters into Second Amendment to Amended and Restated Merger Agreement with Evofem
September 9, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and Evofem Biosciences Inc., a health pioneer commercializing innovative products to address unmet needs in women’s sexual and reproductive health, today announced the signing of the Second Amendment to the Amended and Restated Agreement and Plan of Merger, under which Aditxt […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Seeks Grant Funding to Advance Early Detection, Management of Prostate Cancer
September 4, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc., has submitted a grant application to the Prostate Cancer Research Program (“PCRP”) under the Department of Defense (“DoD”) Implementation Science Award funding mechanism. Pearsanta is seeking $2 million in non-dilutive funding to advance the […]
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
August 29, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, will be participating in next month’s H.C. Wainwright 26th Annual Global Investment Conference. The conference is scheduled for Sept. 9–11, 2024, in New York City. According to the announcement, Aditxt cofounder, CEO and chair Amro Albanna will virtually present at the […]
InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Subsidiary Appoints Industry Veteran as Subsidiary President
August 26, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has announced a new president for its majority-owned subsidiary, Pearsanta Inc. According to the announcement, Christoper Mitton has been named president of the subsidiary, which focuses on precision health. Mitton has an impressive career of leadership in the medical diagnostics space […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement
August 21, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has entered into a third amending agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats. According to the […]
InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update
August 14, 2024
Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Report on Annual Shareholders’ Meeting Activity
August 13, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising innovations, is reporting on the results of its recent annual shareholders’ meeting. According to the announcement, all nine proposed agenda items were successfully passed. Those proposals include the election of directors, the ratification of auditors, and the issuing of shares for Series B-1 […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters into $1.2M Registered Direct Offering Agreement
August 9, 2024
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a securities purchase agreement with certain institutional investors. The agreement outlines a registered direct offering for the purchase and sale of 1,130,189 shares of common stock or common stock equivalents for $1.06 per […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Submits Proposal to CDMRP for Ovarian Cancer Detection Research Award
August 7, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its subsidiary, Pearsanta Inc., has submitted a proposal for the Clinical Trial Translational Endpoints Research Award to the Congressionally Directed Medical Research Programs (“CDMRP”) of the Department of Defense. According to the announcement, the proposal is designed to validate a novel […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement
July 25, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its wholly owned subsidiary, Adivir Inc., have signed a second Amending Agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) regarding its previously announced acquisition agreement. A biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures, Appili has […]
InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Inks Middle East License, Supply Agreement for Proprietary Birth Control Product
July 23, 2024
Evofem Biosciences Inc. (OTCQB: EVFM), a company commercializing innovative products to address unmet needs in women’s sexual and reproductive health, has signed a license and supply agreement for the Middle East rights to Phexxi(R), Evofem’s FDA-approved, hormone-free contraceptive, with private Emirati health care company Pharma 1 Drug Store LLC. Evofem and Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Evofem Biosciences (EVFM) Announce Amended, Restates Merger Agreement
July 17, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, along with its wholly owned subsidiary Adifem Inc., and Evofem Biosciences Inc. (OTCQB: EVFM) have amended and restated their previously announced merger agreement. According to the announcement, the amended and restated agreement addresses several issues, including preclosing matters such as interim financing needs […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Evofem Biosciences (EVFM) Announce Market Partnership with Hello Alpha
June 27, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and Evofem Biosciences Inc. (OTCQB: EVFM) are announcing a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman’s unique needs. Last year, Aditxt entered into a merger agreement with Evofem outlining Aditxt’s plans to acquire […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Merger Target Expects ‘Fourth Consecutive Year of Net Sales Growth’
May 15, 2024
Aditxt (NASDAQ: ADTX) recently provided Evofem Biosciences Inc. (OTCQB: EVFM) $1 million in consideration for reinstating and amending the merger agreement, as amended, between the companies. Aditxt agreed to invest an additional $2.5 million in Evofem by July 1, and the companies are working to close the contemplated transaction in the second half of 2024. […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Securities Purchase Agreements, Anticipates Receiving Approximately $4.2M from Placement
May 3, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has entered into securities purchase agreements. The agreements are for the purchase and sale of 4,186 shares of the Company’s Series C-1 Convertible Preferred Stock and 4,186 shares of the Company’s D-1 Preferred Stock, as well as warrants to purchase approximately 1.65 […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer
April 2, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Acquisition Target Reports Increased Product Sales, Ongoing Revenue Growth
March 27, 2024
Aditxt (NASDAQ: ADTX) previously entered into a definitive agreement to acquire Evofem Biosciences Inc. (OTCQB: EVFM), which is believed to represent a compelling opportunity to accelerate Evofem’s growth trajectory, as a subsidiary of Aditxt, into a multi-product women’s health franchise. Today Evofem, the company behind Phexxi(R) (lactic acid, citric acid and potassium bitartrate) vaginal gel, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Potential Acquisition Releases FY 2023 Preliminary Financial Report
February 1, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a definitive agreement with Evofem Biosciences Inc. (OTCQB: EVFM) late last year, and Evofem is reporting its preliminary financial results for 2023, which include record net sales of Phexxi(R), its hormone-free contraceptive gel. According to the report, Phexxi is seeing a […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Acquires Proprietary EEG Portfolio
January 30, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has announced its acquisition of a portfolio of electroencephalography “EEG” brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care. “This transaction […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Subsidiary Pearsanta Announce Acquisition of MDNA Life Sciences Inc.’s Mitomic(TM) Testing Platform
January 8, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its subsidiary Pearsanta Inc., have announced the acquisition of MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early-disease and cancer-detection platform. According to the announcement, the acquisition “reinforces Pearsanta’s dedication to enhancing patient outcomes through early-disease detection and the power of precision diagnostics.” […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Secures $6M in Private Placement
January 5, 2024
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it has closed its private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains NASDAQ Compliance, Announces $6M Private Placement
January 2, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has regained compliance with NASDAQ’s minimum stockholders’ equity requirement. The company was notified by NASDAQ regarding the compliance issues, which is subject to a mandatory panel monitor until Dec. 29, 2024. In addition, the company announced that it has entered into definitive […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Definitive Agreement to Acquire Evofem Biosciences Inc.
December 12, 2023
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive agreement with Evofem Biosciences Inc. (OTCQB: EVFM), a pioneer in women’s health. The agreement outlines plans for Aditxt to acquire Evofem in a transaction involving the issuance of a combination of common stock and preferred stock as well […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Participation at 8th Annual Dawson James Conference
October 6, 2023
Aditxt (NASDAQ: ADTX) is an innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it will present at the 8th Annual Dawson James Conference on Thursday, Oct. 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida. […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Pearsanta Appoints Ernie Lee as CEO to Drive Launch of Test2Treat.me Platform
October 5, 2023
Aditxt (NASDAQ: ADTX) is a global innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it has appointed Ernie Lee to serve as the chief executive officer of its wholly owned subsidiary Pearsanta Inc. The appointment intends to accelerate the […]
Dawson James Small Cap Growth Conference: Exploring a Changing World of Investment Opportunities
September 26, 2023
Capital marketers, insurance and wealth management experts, investment bankers, individual investors, and research analysts, are invited to attend the Dawson James Small Cap Growth Conference to be held in Wyndham Grand Harborside Jupiter, Jupiter, FL, October 12, 2023. The distinguished conference serves as a hallmark in the financial world, featuring important management experts slated to […]
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
September 21, 2023
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Exec to Present at Upcoming H.C. Wainwright Global Investment Conference
September 8, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, will be participating in the 25th annual H.C. Wainwright Global Investment Conference; the premier event is scheduled for Sept. 11–13, 2023, in New York City. According to the announcement, Aditxt chair, cofounder and CEO Amro Albanna […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on $10M Private Placement
September 7, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has closed on its previously announced private placement. The placement was comprised of the purchase and sale of one million shares of common stock (or prefunded warrants in lieu thereof) at a purchase price of $10 […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Enter $10M Private Placement Agreements
September 1, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into definitive agreements for the purchase and sale of common stock. According to the announcement, the private placements comprise one million shares of common stock (or prefunded warrant in lieu thereof) sold at $10 […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Planned Strategy for Achieving Commercial Scale, Updated Release on 1-for-40 Reverse Split
August 18, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, announced an important update regarding its innovation programs and strategic M&A initiatives. The shareholder update provides the company’s planned strategy for achieving commercial scale. “Aditxt takes a stakeholder-driven approach to […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Effect 1-for-40 Reverse Stock Split
August 17, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has announced that it will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. Eastern Time on Aug. 18, 2023. Commencing with the opening of trading on the Nasdaq Capital Market […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Pearsanta Inc. Enters LOI to Acquire Natural State Laboratories and Natural State Genomics
June 20, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, today announced the signing of an exclusive non-binding letter of intent (“LOI”) by its wholly owned subsidiary, Pearsanta(TM) Inc., to acquire both Natural State Laboratories LLC (“NSL”) and Natural State Genomics LLC (“NSG”) (collectively, “Natural State […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Inks Stiff Person Syndrome Clinical Trial Agreement with Mayo Clinic
May 5, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, and its subsidiary Adimune(TM) Inc. announced a clinical trial agreement with Mayo Clinic. The clinical trial, which is designed to advance clinical studies targeting autoimmune diseases of the central nervous system (“CNS”), is expected to begin this […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on $1.9M Registered Direct Offering
April 25, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it has closed on its previously announced registered direct offering. The company transacted the closing with a single healthcare-focused institutional investor; the closing consisted of the purchase and sale of 1,585,350 shares of common stock […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Registered Direct Offering Expected to Total $1.9M
April 21, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a definitive agreement. The company announced a registered direct offering totaling $1.9 million; the agreement is with a single healthcare-focused institutional investor and includes the purchase and sale of 1,585,350 shares of common […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Inks Asset Purchase Agreement for 50% Ownership of Global Response Aid
April 20, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed an asset purchase agreement with Cellvera Ltd. According to the announcement, the agreement gives Aditxt a 50% ownership in G Response Aid FZE; the remaining 50% ownership belongs to global logistics leader Agility Inc. Calling […]